AIRLINK 72.59 Increased By ▲ 3.39 (4.9%)
BOP 4.99 Increased By ▲ 0.09 (1.84%)
CNERGY 4.29 Increased By ▲ 0.03 (0.7%)
DFML 31.71 Increased By ▲ 0.46 (1.47%)
DGKC 80.90 Increased By ▲ 3.65 (4.72%)
FCCL 21.42 Increased By ▲ 1.42 (7.1%)
FFBL 35.19 Increased By ▲ 0.19 (0.54%)
FFL 9.33 Increased By ▲ 0.21 (2.3%)
GGL 9.82 Increased By ▲ 0.02 (0.2%)
HBL 112.40 Decreased By ▼ -0.36 (-0.32%)
HUBC 136.50 Increased By ▲ 3.46 (2.6%)
HUMNL 7.14 Increased By ▲ 0.19 (2.73%)
KEL 4.35 Increased By ▲ 0.12 (2.84%)
KOSM 4.35 Increased By ▲ 0.10 (2.35%)
MLCF 37.67 Increased By ▲ 1.07 (2.92%)
OGDC 137.75 Increased By ▲ 4.88 (3.67%)
PAEL 23.41 Increased By ▲ 0.77 (3.4%)
PIAA 24.55 Increased By ▲ 0.35 (1.45%)
PIBTL 6.63 Increased By ▲ 0.17 (2.63%)
PPL 125.05 Increased By ▲ 8.75 (7.52%)
PRL 26.99 Increased By ▲ 1.09 (4.21%)
PTC 13.32 Increased By ▲ 0.24 (1.83%)
SEARL 52.70 Increased By ▲ 0.70 (1.35%)
SNGP 70.80 Increased By ▲ 3.20 (4.73%)
SSGC 10.54 No Change ▼ 0.00 (0%)
TELE 8.33 Increased By ▲ 0.05 (0.6%)
TPLP 10.95 Increased By ▲ 0.15 (1.39%)
TRG 60.60 Increased By ▲ 1.31 (2.21%)
UNITY 25.10 Decreased By ▼ -0.03 (-0.12%)
WTL 1.28 Increased By ▲ 0.01 (0.79%)
BR100 7,566 Increased By 157.7 (2.13%)
BR30 24,786 Increased By 749.4 (3.12%)
KSE100 71,902 Increased By 1235.2 (1.75%)
KSE30 23,595 Increased By 371 (1.6%)

Drug importers have been forced to stop importing most of the foreign medicines owing to massive depreciation of Pakistani rupee against the US dollar and are of the view that imported drugs have now become too expensive to earn profit in local market.

According to drug market sources, dollar value against Pakistani currency during 2018-19 witnessed an increase of 50 percent while the government is not allowing increase in prices of imported drugs.

Since 2018-19, Pak rupee exchange rate against dollar has gone up from Rs 106 to around Rs 155 while prices of imported drugs are not revised and as a result, importers have stopped importing some medicines. Moreover, almost 40 percent imported drugs in Pakistan are coming from India and Indian companies are not willing to sell their products to Pakistanis. Resultantly, import of these drugs from other markets such as Germany puts additional costs on Pakistani buyers, they added. An official of Drug Regulatory Authority of Pakistan (DRAP) said that presently, drug inspectors have intensified checking of unregistered medicines being sold at pharmacies/chemists. Due to this exercise, shopkeepers have stopped keeping unregistered imported medicines which are smuggled into the country.

A senior official of Pakistan Pharmaceutical Manufacturing Association (PPMA) told Business Recorder that Pakistan at present is not only facing serious shortage of cancer related medicines but supply of drugs being used for the treatment of other diseases is also short owing to government policies and rupee depreciation. For example, imported vaccines for flu and rabies and Furolin, an imported medicine to treat urinary tract infection, are not available in market.

The prices of injections used for CT scan contrast and MRI contrast have been increased from Rs 1,650-2,000 to Rs 4,500 and above. Similarly, import of Nutraceuticals Skin Active skincare products has almost been stopped.

The official said that local drug manufacturers are also facing serious problems owing to regular increase in gas/electricity prices and other input costs including labor. However, the government wants them to sell the products at fixed rates. The PPMA official said that globally up to 105-110 molecules' prices are regulated and rest of the product prices are left on the market forces, while in Pakistan prices of each and every product is regulated.

Copyright Business Recorder, 2019

Comments

Comments are closed.